biote (BTMD) AI Stock Analysis

• Market Cap: $94.71M
• Dividend Yield: N/A
• Average Volume (3M): 108.96K
• Price to Earnings (P/E): 3.3
• Beta (1Y): 0.92
• Revenue Growth: 1.34%
• EPS Growth: 185.03%
• Country: US
• Employees: 217
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 0.22
• Shares Outstanding: 33,280,228
• 10 Day Avg. Volume: 116,982
• 30 Day Avg. Volume: 108,956
• PEG Ratio: -2.30
• Price to Book (P/B): -2.00
• Price to Sales (P/S): 1.07
• P/FCF Ratio: 5.46
• Enterprise Value/Market Cap: 2.49
• Enterprise Value/Revenue: 1.19
• Enterprise Value/Gross Profit: 1.65
• Enterprise Value/Ebitda: 4.20
• 1Y Price Target: $3.67
• Price Target Upside: 49.19% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): 0.58
• Revenue Forecast (FY): $192.73M

• Rating: 47 Neutral
• Price Target: $2.50 ▲(1.63% Upside)

Biote's overall stock score reflects significant financial challenges and bearish technical indicators. Despite a low P/E ratio suggesting potential undervaluation, the company's high leverage, declining revenue, and liquidity concerns weigh heavily on its outlook. The earnings call provided some optimism with growth in dietary supplements and improved margins, but the impact of strategic initiatives remains uncertain.

Positive Factors

Dietary Supplements Growth

The growth in dietary supplements, driven by e-commerce, indicates a successful diversification strategy, enhancing revenue stability.

Gross Profit Margin Improvement

Improved gross profit margins reflect effective cost management and vertical integration, supporting long-term profitability.

Increased Cash Flow from Operations

Increased cash flow from operations strengthens liquidity and provides flexibility for strategic investments and debt management.

Negative Factors

Revenue Decline

The decline in revenue highlights challenges in maintaining sales momentum, which could affect long-term growth prospects.

High Leverage

High leverage and negative equity position increase financial risk, potentially limiting future borrowing capacity and investment.

Sales Team Transition Impact

Sales team restructuring has disrupted revenue generation, posing a risk to short-term performance and market competitiveness.

biote Business Overview & Revenue Model

Company Description

biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements. It also sells Biote-branded dietary supplements; and sterile pellet insertion kits for men and women. The company was founded in 2011 and is headquartered in Irvine, Texas.

How the Company Makes Money

Biote generates revenue primarily through the sale of its hormone replacement therapy products and services. The company's revenue model is built on a subscription basis for healthcare providers who utilize Biote's training, support, and products in their practice. Key revenue streams include the direct sale of hormone therapy products, service fees for training healthcare professionals, and ongoing support services. Additionally, Biote may benefit from partnerships with healthcare providers and clinics, which can enhance its market reach and customer base, further contributing to its earnings.

biote Financial Statement Overview

Summary

Biote's financial performance is under pressure with declining revenue and profitability. The company has a strong gross profit margin, but negative revenue growth and high leverage present significant risks. Cash flow generation is also strained, indicating liquidity challenges.

Income Statement

The income statement shows a mixed performance. The company has a strong gross profit margin of 71.89% TTM, indicating efficient cost management. However, the net profit margin has decreased to 15.73% TTM from 23.40% in 2021, reflecting declining profitability. Revenue growth has turned negative at -15.3% TTM, suggesting challenges in maintaining sales momentum. EBIT and EBITDA margins have improved TTM, but the overall revenue decline is concerning.

Balance Sheet

The balance sheet reveals significant financial instability. The company has a negative stockholders' equity of -$78.84 million TTM, leading to a negative debt-to-equity ratio of -1.37 TTM, indicating high leverage and financial risk. Return on equity is also negative, reflecting poor returns for shareholders. The equity ratio is negative, highlighting a precarious financial position with liabilities exceeding assets.

Cash Flow

Cash flow analysis shows some resilience despite challenges. Operating cash flow to net income ratio is 0.82 TTM, indicating reasonable cash generation relative to net income. However, free cash flow growth is negative at -4.95% TTM, reflecting declining cash reserves. The free cash flow to net income ratio is 0.84 TTM, suggesting that cash flow is not fully covering net income, which could strain liquidity.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	199.07M	197.19M	185.36M	164.96M	139.40M	116.57M
Gross Profit	143.11M	139.06M	127.48M	110.38M	90.58M	71.64M
EBITDA	56.24M	15.59M	9.23M	7.96M	35.98M	32.91M
Net Income	31.31M	3.16M	3.32M	-969.00K	32.62M	29.16M
Balance Sheet
Total Assets	104.80M	122.37M	155.29M	111.64M	54.33M	32.59M
Cash, Cash Equivalents and Short-Term Investments	19.60M	39.34M	89.00M	79.23M	26.77M	17.21M
Total Debt	107.89M	110.86M	114.87M	120.43M	37.34M	42.35M
Total Liabilities	183.64M	224.57M	191.84M	169.92M	50.20M	49.66M
Stockholders Equity	-78.84M	-105.93M	-29.40M	-44.46M	4.13M	-17.07M
Cash Flow
Free Cash Flow	34.98M	38.81M	24.17M	-10.99M	29.91M	25.03M
Operating Cash Flow	41.48M	45.24M	26.88M	-9.16M	33.72M	26.43M
Investing Cash Flow	-7.09M	-18.80M	-2.71M	-1.84M	-3.81M	-1.39M
Financing Cash Flow	-41.19M	-76.08M	-14.38M	63.46M	-20.34M	-18.32M

biote Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.46
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BTMD, the sentiment is Negative. The current price of 2.46 is below the 20-day moving average (MA) of 2.84, below the 50-day MA of 3.02, and below the 200-day MA of 3.68, indicating a bearish trend. The MACD of -0.10 indicates Positive momentum. The RSI at 39.67 is Neutral, neither overbought nor oversold. The STOCH value of 18.18 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BTMD.

biote Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
JYNT	49 Neutral	$116.10M	64.43	-1.37%	―	-54.93%	―
BTMD	47 Neutral	$94.71M	3.28	―	―	1.34%	185.03%
CCM	44 Neutral	$22.84M	-1.01	―	―	-22.38%	56.66%
CCEL	44 Neutral	$34.94M	-73.26	―	9.90%	-0.29%	94.56%
DCGO	43 Neutral	$108.57M	―	-17.32%	―	-47.03%	-274.41%
PIII	40 Underperform	$60.81M	-0.17	-138.17%	―	4.20%	-54.16%

biote Corporate Events

Biote Corp. Navigates Challenges in Latest Earnings Call

Biote Corp.’s latest earnings call revealed a mixed sentiment, with challenges and opportunities shaping the company’s financial landscape. While the company faced hurdles such as declining procedure revenue and adjusted EBITDA due to commercial team transformations and higher attrition rates, there were positive developments. Growth in dietary supplements, improved gross profit margins, increased cash flow, and strategic share repurchases provided a silver lining. Additionally, a successful marketing event reinforced Biote’s market leadership.

Biote Corp. Reports Q3 2025 Financial Results

Biote Corp., a company specializing in hormone optimization and healthy aging solutions, is a prominent player in the healthcare sector, focusing on enhancing the healthspan of patients through innovative approaches. In its latest earnings report for the third quarter of 2025, Biote Corp. reported a revenue of $48.0 million, with a gross profit margin of 71.8%. The company also highlighted its strategic priorities, including accelerating growth from new providers and maximizing value from top-tier clinics.